Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Liraglutide (Primary)
Indications Ischaemic heart disorders; Obesity; Prediabetic state; Type 2 diabetes mellitus
Focus Therapeutic Use

08 Jul 2013 Primary endpoint 'Bodyweight-reduction' has been met.
22 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
12 Feb 2013 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com